Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
igermetostat + cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone
- Development stage
- Unknown
- Lead developer
- Evopoint Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
XNW5004 + CHOEP is a combination regimen consisting of the novel EZH2 inhibitor igermetostat (XNW5004) and the standard chemotherapy backbone CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). Igermetostat is a selective, substrate-competitive small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), which is the catalytic subunit of the polycomb repressive complex 2 (PRC2) responsible for histone H3 lysine 27 (H3K27) methylation. Developed by Evopoint Biosciences, this combination is primarily being evaluated for the treatment of patients with newly diagnosed peripheral T-cell lymphoma (PTCL). The regimen aims to combine the epigenetic modulating effects of igermetostat with the cytotoxic activity of the CHOEP regimen to improve outcomes in untreated PTCL patients.
- Other names
- Igermetostat + CHOEP
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on igermetostat + cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on igermetostat + cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone.